Skip to main content

Xenon Pharmaceuticals Inc.

corporate_fare Company Profile

Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed XENE - Latest Insights

XENE
Apr 22, 2026, 4:02 PM EDT
Filing Type: DEF 14A
Importance Score:
7
XENE
Mar 12, 2026, 4:23 PM EDT
Source: Wiseek News
Importance Score:
8
XENE
Mar 12, 2026, 4:17 PM EDT
Filing Type: 8-K
Importance Score:
9
XENE
Mar 11, 2026, 5:47 PM EDT
Filing Type: 424B5
Importance Score:
9
XENE
Mar 10, 2026, 10:41 PM EDT
Source: Reuters
Importance Score:
8
XENE
Mar 10, 2026, 9:23 PM EDT
Filing Type: FWP
Importance Score:
7
XENE
Mar 09, 2026, 4:54 PM EDT
Filing Type: 424B5
Importance Score:
9
XENE
Mar 09, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
9
XENE
Mar 09, 2026, 7:36 AM EDT
Filing Type: 8-K
Importance Score:
9
XENE
Mar 09, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
XENE
Feb 27, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
7
XENE
Feb 26, 2026, 4:12 PM EST
Filing Type: 10-K
Importance Score:
8
XENE
Feb 26, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
8